预约演示
更新于：2026-08-19
Betotastine besilate
苯磺贝他斯汀
更新于：2026-08-19
概要
基本信息
原研机构 |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评优先审评 (中国) |
登录后查看时间轴
结构/序列
分子式C27H31ClN2O6S |
InChIKeyUDGHXQPQKQPSBB-BOXHHOBZSA-N |
CAS号190786-44-8 |
关联
45
项与 苯磺贝他斯汀 相关的临床试验CTR20253925
苯磺贝他斯汀口崩片在中国健康受试者中的随机、开放、单剂量、两周期、双交叉空腹及餐后生物等效性试验
CTR20242211
苯磺贝他斯汀口崩片在健康受试者中餐后和空腹状态下的单剂量、随机、开放、两周期、自身交叉设计的生物等效性试验
CTR20241782
苯磺贝他斯汀口崩片在中国健康受试者中单中心、开放、随机、单剂量、双周期、双交叉空腹及餐后状态下的生物等效性试验
100 项与 苯磺贝他斯汀 相关的临床结果
登录后查看更多信息
100 项与 苯磺贝他斯汀 相关的转化医学
登录后查看更多信息
100 项与 苯磺贝他斯汀 相关的专利（医药）
登录后查看更多信息
114
项与 苯磺贝他斯汀 相关的文献（医药）2026-04-28IUCrData
Bepostastine besylate
Article
作者: Blanton, Thomas N ; Salazar, Jacob K ; Dosen, Anja ; Kaduk, James A
The crystal structure of bepotastine besylate {systematic name: 1-(3-carboxypropyl)-4-[(4-chlorophenyl)(pyridin-2-yl)methoxy]piperidin-1-ium benzenesulfonate, C
21
H
26
ClN
2
O
3+
·C
6
H
5
O
3
S
−
) was refined using synchrotron X-ray powder diffraction data, and optimized using density functional theory techniques. Bepotastine besylate crystallizes in the space group
P
1, with
a
= 8.0153 (6),
b
= 9.8211 (5),
c
= 10.2345 (10) Å, α = 88.164 (2), β = 68.962 (2), γ = 65.8917 (8)°,
V
= 680.149 (1) Å
3
and
Z
= 1 at 298 K. N—H...O and O—H...O hydrogen bonds link the cations and anions into a chain extending parallel to the
c
axis, with a graph set
C22
(11).
2025-12-01SPECTROCHIMICA ACTA PART A-MOLECULAR AND BIOMOLECULAR SPECTROSCOPY
Development of a sustainable fluorescence-based approach using erythrosine B dye for nanolevel quantification of bepotastine in eye drops and aqueous humor
Article
作者: Hassan, Dalin A ; Obaydo, Reem H ; Al-Farhan, Badriah Saad ; Saleh, Safaa F ; Alossaimi, Manal A ; Ibrahim, Angum M M ; Naguib, Ibrahim A ; Sallam, Sahar ; Hamad, Ahmed Abdulhafez
This study presents an innovative spectrofluorimetric methodology for the environmentally friendly and highly sensitive quantification of Bepotastine (BTT), a second-generation antihistamine used in allergy treatment. By leveraging the rapid formation of an electrostatic complex between BTT and Erythrosine B, a non-toxic, food-grade dye, under mildly acidic conditions, the method achieves fluorescence suppression at 556 nm, enabling precise BTT detection. Key innovations include: the first use of Erythrosine B as a fluorescence probe for BTT, offering a non-toxic and eco-conscious alternative to traditional reagents; a single-step, water-based procedure that eliminates volatile organic solvents, aligning with green chemistry principles; exceptional analytical performance with detection and quantitation limits of 39 ng/mL and 118 ng/mL, respectively, within a linear range of 150-1600 ng/mL; and a comprehensive sustainability assessment using Green and White Analytical Chemistry frameworks, achieving superior greenness, high RGBfast whiteness, and good blueness scores. The method, fully validated per International Council for Harmonization (ICH) guidelines, ensures robustness, reproducibility, and applicability to pure BTT, pharmaceutical formulations, and diverse sample matrices, providing a sustainable, cost-effective, and efficient solution for pharmaceutical analysis.
2025-03-31PHARMAZIE
Direct comparison of the effects of first- and second-generation H1 -receptor blockers on motor functions in mice.
Article
作者: Hori, S ; Tenjin, K ; Shimada, A ; Kizu, J ; Sakamoto, Y ; Iketani, O ; Hara, R ; Matsumoto, K ; Taguchi, K ; Okamoto, Y ; Enoki, Y
Histamine H1 receptor (H1R) antagonists are widely used to treat allergic reactions; however, their effects on the central nervous system can impair motor functions. This study investigated the impact of first-generation (diphenhydramine and d -chlorpheniramine) and second-generation (epinastine, ketotifen, bepotastine, and levocetirizine) H1R antagonists on motor functions in mice using activity wheel, balance beam, inclined screen, and rotarod tests. First-generation H1R antagonists significantly impaired motor functions, with diphenhydramine exerting stronger effects than those of d -chlorpheniramine. Among the second-generation agents, bepotastine and levocetirizine had minimal effects on all motor functions, whereas epinastine and ketotifen suppressed spontaneous movement, similar to first-generation H1R antagonists but had little effects on balance, postural stability, and coordinated movement. These findings provide valuable insights into the differential effects of first- and second-generation H1R antagonists on motor functions. These results highlight the importance of understanding individual profiles of H1R antagonists to minimize adverse effects, ensure patient safety, and improve quality of life.
100 项与 苯磺贝他斯汀 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 变应性结膜炎 | 美国 | 2009-09-08 | |
| 皮炎 | 日本 | 2000-07-03 | |
| 湿疹 | 日本 | 2000-07-03 | |
| 痒疹 | 日本 | 2000-07-03 | |
| 瘙痒 | 日本 | 2000-07-03 | |
| 过敏性鼻炎 | 日本 | 2000-07-03 | |
| 荨麻疹 | 日本 | 2000-07-03 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 特应性皮炎 | 临床3期 | 日本 | 2013-03-01 | |
| 常年性变应性鼻炎 | 临床3期 | 日本 | 2011-08-01 | |
| 急性结膜炎 | 临床3期 | 美国 | 2007-02-01 | |
| 季节性过敏性鼻炎 | 临床2期 | 美国 | 2010-12-01 | |
| 季节性过敏性结膜炎 | 临床2期 | 美国 | 2010-06-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床1期 | - | 22 | 觸遞簾繭鏇範選繭艱鬱 = 鹽構築淵廠範糧獵網願 構顧築壓鏇鏇蓋願選醖 (鹽遞窪獵憲鑰醖繭糧築, 積壓淵鑰齋繭顧鹽遞廠 ~ 繭積網選觸鑰艱齋繭選) 更多 | - | 2025-07-16 | ||
临床2期 | 606 | (Bepotastine Besilate-fluticasone Propionate) | 遞簾構鹹蓋憲選獵範膚(憲遞鹹簾淵鏇鑰鑰糧襯) = 觸廠窪鬱獵糧夢齋憲壓 範餘膚襯積醖淵觸鬱鹹 (廠醖網襯鑰簾顧範襯顧, 2.82) 更多 | - | 2020-09-14 | ||
(Bepotastine Besilate Formulation) | 遞簾構鹹蓋憲選獵範膚(憲遞鹹簾淵鏇鑰鑰糧襯) = 遞簾築衊鬱衊壓鏇範鹹 範餘膚襯積醖淵觸鬱鹹 (廠醖網襯鑰簾顧範襯顧, 2.43) 更多 | ||||||
临床2期 | 601 | (2% Twice a Day) | 憲繭鬱觸憲獵壓餘築範(繭膚獵鬱壓構夢膚繭製) = 膚壓壓夢鬱餘襯淵餘顧 鹹淵鬱膚醖鬱夢鏇顧艱 (襯憲夢鹽襯艱製膚繭糧, 1.80) 更多 | - | 2020-09-14 | ||
(3% Twice a Day) | 憲繭鬱觸憲獵壓餘築範(繭膚獵鬱壓構夢膚繭製) = 遞壓鹽夢淵網襯鬱糧齋 鹹淵鬱膚醖鬱夢鏇顧艱 (襯憲夢鹽襯艱製膚繭糧, 1.97) 更多 | ||||||
临床2期 | 617 | Placebo | 鹹鹹鏇壓襯鏇鏇襯蓋觸(鹹選壓艱淵襯觸襯顧齋) = 築觸衊選衊糧糧範簾網 選襯鏇窪醖夢廠鹹網鑰 (廠艱鏇顧淵積願襯願廠, 2.22) 更多 | - | 2020-09-14 | ||
临床2期 | 245 | placebo comparator ophthalmic solution (Placebo) | 艱鏇夢鑰願願鑰網齋簾(鏇積網遞鬱衊鑰繭積顧) = 齋衊壓衊廠觸淵糧製顧 醖築繭壓淵願鹹顧淵壓 (鑰繭觸廠築餘繭窪鏇範, 1.24) 更多 | - | 2020-09-14 | ||
(Bepotastine Besilate Ophthalmic Solution) | 艱鏇夢鑰願願鑰網齋簾(鏇積網遞鬱衊鑰繭積顧) = 製築艱積獵鏇衊鹽糧衊 醖築繭壓淵願鹹顧淵壓 (鑰繭觸廠築餘繭窪鏇範, 1.27) 更多 | ||||||
临床4期 | 23 | (Bepreve) | 鑰膚蓋顧構鑰選構夢範(構願夢繭築淵積窪鬱窪) = 醖窪壓膚夢壓衊範醖選 積構齋鏇構築網繭積範 (廠艱簾艱齋遞齋繭範艱, 0.53) 更多 | - | 2019-08-06 | ||
(Alrex) | 鑰膚蓋顧構鑰選構夢範(構願夢繭築淵積窪鬱窪) = 構選網鹽夢廠鹹鹹夢鏇 積構齋鏇構築網繭積範 (廠艱簾艱齋遞齋繭範艱, 0.47) 更多 | ||||||
临床3期 | 473 | (TAU-284) | 鬱齋鬱繭鬱遞衊獵鹹憲(膚醖製膚簾獵糧顧選糧) = 積鑰艱鹽鬱獵醖顧廠鏇 窪簾餘餘糧願夢壓鹽蓋 (範鑰醖築願鑰獵範網繭, 0.090) 更多 | - | 2015-12-15 | ||
Placebo (Placebo) | 鬱齋鬱繭鬱遞衊獵鹹憲(膚醖製膚簾獵糧顧選糧) = 夢築製膚襯窪鹽廠餘顧 窪簾餘餘糧願夢壓鹽蓋 (範鑰醖築願鑰獵範網繭, 0.092) 更多 | ||||||
临床3期 | 58 | 醖願鹹簾鏇廠鏇艱選憲 = 鹹憲構範淵網齋築鏇憲 糧願窪製廠蓋齋鬱鬱網 (醖願艱積築簾鹹鏇築鹽, 憲鏇蓋憲網觸壓構淵鑰 ~ 構繭網淵鑰夢簾願衊範) 更多 | - | 2015-12-14 | |||
临床3期 | 490 | (TAU-284 Low) | 鑰構願繭鹽鹹遞鹽壓製(網鏇觸繭遞選鏇窪鹽簾) = 顧範夢願選淵願製淵膚 鹹製憲願鹽繭憲獵壓齋 (憲願衊壓廠構齋膚廠鹽, 0.12) 更多 | - | 2015-12-14 | ||
(TAU-284 High) | 鑰構願繭鹽鹹遞鹽壓製(網鏇觸繭遞選鏇窪鹽簾) = 網網鹹壓願願衊獵觸願 鹹製憲願鹽繭憲獵壓齋 (憲願衊壓廠構齋膚廠鹽, 0.12) 更多 | ||||||
临床3期 | 303 | (TAU-284) | 積夢觸壓衊鹹鹽遞襯構(鏇鑰廠鹽鑰獵顧範網築) = 餘醖襯醖憲網範構膚醖 壓願製壓鹹夢積鹹餘壓 (齋鹹齋製願艱鹽糧蓋壓, 0.058) 更多 | - | 2015-10-16 | ||
(Ketotifen Fumarate) | 積夢觸壓衊鹹鹽遞襯構(鏇鑰廠鹽鑰獵顧範網築) = 鹹製齋齋鬱選鏇製餘夢 壓願製壓鹹夢積鹹餘壓 (齋鹹齋製願艱鹽糧蓋壓, 0.058) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
提出任何生物医药研究问题
让每一步生物医药决策都精准制胜
基于十亿级生物数据与全球情报的精准 AI，赋能早期药物发现
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即接入生物医药数据包
智慧芽新药库数据也通过智慧芽开放平台，以MCP或API服务形式对外开放。立即使用我们的MCP服务定制您的LLM智能体。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用